- Page 1 and 2:
Clinical Manual for Management of t
- Page 3 and 4:
Table of Contents Clinical Manual f
- Page 5 and 6:
Clinical Manual for Management of t
- Page 7 and 8:
Preface—About this Manual | Clini
- Page 9:
Previous Editions Atlanta Contribut
- Page 12 and 13:
♦ ♦ ♦ ♦ ♦ | Clinical Manu
- Page 14 and 15:
1-2 | Clinical Manual for Managemen
- Page 16 and 17:
1-4 | Clinical Manual for Managemen
- Page 18 and 19:
1-6 | Clinical Manual for Managemen
- Page 20 and 21:
1-8 | Clinical Manual for Managemen
- Page 23 and 24:
Initial Physical Examination Backgr
- Page 25 and 26:
Genitals/Rectum • Inspect the gen
- Page 27 and 28:
Initial and Interim Laboratory and
- Page 29 and 30:
Section 1—Testing and Assessment
- Page 31:
Patient Education ♦ ♦ ♦ ♦ D
- Page 34 and 35:
1-22 | Clinical Manual for Manageme
- Page 36 and 37:
1-24 | Clinical Manual for Manageme
- Page 38 and 39:
1-26 | Clinical Manual for Manageme
- Page 40 and 41:
1-28 | Clinical Manual for Manageme
- Page 42 and 43:
1-30 | Clinical Manual for Manageme
- Page 44 and 45:
1-32 | Clinical Manual for Manageme
- Page 46 and 47:
1-34 | Clinical Manual for Manageme
- Page 48 and 49:
1-36 | Clinical Manual for Manageme
- Page 51 and 52:
Section 2—Health Maintenance and
- Page 53:
References ♦ ♦ ♦ ♦ ♦ ♦
- Page 56 and 57:
2-6 | Clinical Manual for Managemen
- Page 58 and 59:
2-8 | Clinical Manual for Managemen
- Page 60 and 61:
2-10 | Clinical Manual for Manageme
- Page 62 and 63:
2-12 | Clinical Manual for Manageme
- Page 64 and 65:
2-14 | Clinical Manual for Manageme
- Page 67 and 68:
Occupational Postexposure Prophylax
- Page 69 and 70:
P: Plan Laboratory Testing Provide
- Page 71 and 72:
For hepatitis C, no recommended pro
- Page 73 and 74:
Section 2—Health Maintenance and
- Page 75 and 76:
as hepatitis C or another sexually
- Page 77 and 78:
for treatment is appropriate, and b
- Page 79 and 80:
Section 2—Health Maintenance and
- Page 81 and 82:
contact with the patient. Patients
- Page 83 and 84:
tablet daily of trimethoprim-sulfam
- Page 85 and 86:
Opportunistic Infection Prophylaxis
- Page 87 and 88:
Discontinuing Primary Prophylaxis P
- Page 89 and 90:
Latent Tuberculosis Background Late
- Page 91 and 92:
INH may cause liver toxicity and it
- Page 93:
Patient Education ♦ ♦ ♦ ♦
- Page 96 and 97:
2-46 | Clinical Manual for Manageme
- Page 98 and 99:
3-2 | Clinical Manual for Managemen
- Page 100 and 101:
3-4 | Clinical Manual for Managemen
- Page 102 and 103:
3-6 | Clinical Manual for Managemen
- Page 104 and 105:
3-8 | Clinical Manual for Managemen
- Page 106 and 107:
3-10 | Clinical Manual for Manageme
- Page 108 and 109:
3-12 | Clinical Manual for Manageme
- Page 110 and 111:
3-14 | Clinical Manual for Manageme
- Page 112 and 113:
3-16 | Clinical Manual for Manageme
- Page 114 and 115:
3-18 | Clinical Manual for Manageme
- Page 117 and 118:
Reducing Maternal-Infant HIV Transm
- Page 119 and 120:
Some states require written informe
- Page 121 and 122:
contraindicated during pregnancy be
- Page 123 and 124:
Section 3—Antiretroviral Therapy
- Page 125 and 126:
Nelfinavir (Viracept) Adequate drug
- Page 127 and 128:
Section 3—Antiretroviral Therapy
- Page 129 and 130:
Section 3—Antiretroviral Therapy
- Page 131 and 132:
Patient Education ♦ ♦ ♦ ♦
- Page 133:
♦ ♦ ♦ ♦ ♦ ♦ ♦ ♦ ♦
- Page 136 and 137:
3-40 | Clinical Manual for Manageme
- Page 138 and 139:
3-42 | Clinical Manual for Manageme
- Page 140 and 141:
3-44 | Clinical Manual for Manageme
- Page 142 and 143:
3-46 | Clinical Manual for Manageme
- Page 144 and 145:
3-48 | Clinical Manual for Manageme
- Page 146 and 147:
3-50 | Clinical Manual for Manageme
- Page 148 and 149:
3-52 | Clinical Manual for Manageme
- Page 150 and 151:
4-2 | Clinical Manual for Managemen
- Page 152 and 153:
4-4 | Clinical Manual for Managemen
- Page 154 and 155: 4-6 | Clinical Manual for Managemen
- Page 156 and 157: 4-8 | Clinical Manual for Managemen
- Page 158 and 159: 4-10 | Clinical Manual for Manageme
- Page 160 and 161: 4-12 | Clinical Manual for Manageme
- Page 162 and 163: 4-14 | Clinical Manual for Manageme
- Page 165 and 166: Section 4—Complications of Antire
- Page 167 and 168: ♦ ♦ ♦ Toronto General Hospita
- Page 169 and 170: Adverse Reactions to HIV Medication
- Page 171 and 172: ♦ ♦ ♦ ♦ ♦ Vital signs: No
- Page 173 and 174: egimen, symptoms of fatigue could i
- Page 175 and 176: Recreational Drugs and Antiretrovir
- Page 177 and 178: Section 4—Complications of Antire
- Page 179 and 180: LSD, Mescaline, Psilocin, and Methy
- Page 181 and 182: Immune Reconstitution Syndrome Back
- Page 183 and 184: A: Assessment In the appropriate cl
- Page 185 and 186: ♦ ♦ ♦ ♦ ♦ Navas E, Martin
- Page 187 and 188: 5-2 | Clinical Manual for Managemen
- Page 189 and 190: 5-4 | Clinical Manual for Managemen
- Page 191 and 192: 5-6 | Clinical Manual for Managemen
- Page 193 and 194: 5-8 | Clinical Manual for Managemen
- Page 195 and 196: 5-10 | Clinical Manual for Manageme
- Page 197 and 198: 5-12 | Clinical Manual for Manageme
- Page 199 and 200: 5-14 | Clinical Manual for Manageme
- Page 202 and 203: Eye Problems Background The immunos
- Page 206 and 207: Fatigue Background Fatigue is defin
- Page 208: Patient Education ♦ ♦ ♦ ♦
- Page 211 and 212: 5-26 | Clinical Manual for Manageme
- Page 213 and 214: 5-28 | Clinical Manual for Manageme
- Page 215 and 216: 5-30 | Clinical Manual for Manageme
- Page 218 and 219: Nausea and Vomiting Background Naus
- Page 220: ♦ ♦ ♦ Lorazepam (Ativan) may
- Page 223 and 224: 5-38 | Clinical Manual for Manageme
- Page 225 and 226: 5-40 | Clinical Manual for Manageme
- Page 227 and 228: 5-42 | Clinical Manual for Manageme
- Page 230 and 231: Vaginitis/Vaginosis Background Vagi
- Page 232 and 233: Treatment: Alternative regimens ♦
- Page 234 and 235: Anal Dysplasia Background Anal canc
- Page 236: Patient Education ♦ ♦ ♦ Women
- Page 239 and 240: 6-6 | Clinical Manual for Managemen
- Page 242 and 243: Candidiasis, Vulvovaginal Backgroun
- Page 244: Patient Education ♦ ♦ ♦ ♦
- Page 247 and 248: 6-14 | Clinical Manual for Manageme
- Page 250 and 251: Cryptococcal Disease Background Cry
- Page 252: up to 30 mL of CSF to lower the ICP
- Page 255 and 256:
6-22 | Clinical Manual for Manageme
- Page 258 and 259:
Cytomegalovirus Disease Background
- Page 260 and 261:
CMV retinitis Treatment consists of
- Page 262 and 263:
Dermatologic Staphylococcal Infecti
- Page 264:
Known or suspected MSSA SSTI Treat
- Page 267 and 268:
6-34 | Clinical Manual for Manageme
- Page 269 and 270:
6-36 | Clinical Manual for Manageme
- Page 271 and 272:
6-38 | Clinical Manual for Manageme
- Page 273 and 274:
6-40 | Clinical Manual for Manageme
- Page 275 and 276:
6-42 | Clinical Manual for Manageme
- Page 277 and 278:
6-44 | Clinical Manual for Manageme
- Page 279 and 280:
6-46 | Clinical Manual for Manageme
- Page 282 and 283:
Herpes Zoster/Shingles Background S
- Page 284 and 285:
Histoplasmosis Background Histoplas
- Page 286:
Patient Education ♦ ♦ ♦ ♦ H
- Page 289 and 290:
6-56 | Clinical Manual for Manageme
- Page 291 and 292:
6-58 | Clinical Manual for Manageme
- Page 293 and 294:
6-60 | Clinical Manual for Manageme
- Page 295 and 296:
6-62 | Clinical Manual for Manageme
- Page 297 and 298:
6-64 | Clinical Manual for Manageme
- Page 299 and 300:
6-66 | Clinical Manual for Manageme
- Page 301 and 302:
6-68 | Clinical Manual for Manageme
- Page 303 and 304:
6-70 | Clinical Manual for Manageme
- Page 305 and 306:
6-72 | Clinical Manual for Manageme
- Page 308 and 309:
Section 6—Disease-Specific Treatm
- Page 310 and 311:
Table 1. World Health Organization
- Page 312:
Table 3. Monitoring for Toxicity Si
- Page 315 and 316:
6-82 | Clinical Manual for Manageme
- Page 318 and 319:
Pelvic Inflammatory Disease Backgro
- Page 320 and 321:
Table 1. Treatment Regimens for Pel
- Page 322 and 323:
Pneumocystis Pneumonia Background P
- Page 324 and 325:
Table 1. Standard and Alternative P
- Page 326 and 327:
Progressive Multifocal Leukoencepha
- Page 328 and 329:
Seborrheic Dermatitis Background Se
- Page 330 and 331:
Sinusitis Background Sinusitis is d
- Page 332 and 333:
Syphilis Background Syphilis is a s
- Page 334 and 335:
Treponemal antibody tests (TP-PA [T
- Page 336:
Some patients retain reactive (low-
- Page 339 and 340:
6-106| Clinical Manual for Manageme
- Page 341 and 342:
6-108| Clinical Manual for Manageme
- Page 343 and 344:
6-110| Clinical Manual for Manageme
- Page 345 and 346:
6-112| Clinical Manual for Manageme
- Page 347 and 348:
6-114| Clinical Manual for Manageme
- Page 349 and 350:
6-116| Clinical Manual for Manageme
- Page 351 and 352:
6-118| Clinical Manual for Manageme
- Page 353 and 354:
6-120| Clinical Manual for Manageme
- Page 355 and 356:
6-122| Clinical Manual for Manageme
- Page 357 and 358:
Pain Syndrome and Peripheral Neurop
- Page 359 and 360:
Pharmacologic interventions The fol
- Page 361 and 362:
Patient Education ♦ ♦ ♦ ♦
- Page 363 and 364:
Palliative Care and HIV Background
- Page 365 and 366:
GASTROINTESTINAL Nausea, vomiting
- Page 367:
Advance Care Planning Advance care
- Page 370 and 371:
8-2 | Clinical Manual for Managemen
- Page 373 and 374:
Depression Background Major depress
- Page 375 and 376:
of symptoms. The risk of recurrence
- Page 377 and 378:
Panic Disorder Background Panic dis
- Page 379:
♦ If benzodiazepines are used, th
- Page 382 and 383:
8-14 | Clinical Manual for Manageme
- Page 384 and 385:
8-16 | Clinical Manual for Manageme
- Page 386 and 387:
8-18 | Clinical Manual for Manageme
- Page 388 and 389:
8-20 | Clinical Manual for Manageme
- Page 390 and 391:
9-2 | Clinical Manual for Managemen
- Page 392 and 393:
9-4 | Clinical Manual for Managemen
- Page 395 and 396:
Sulfa Desensitization Background Tr
- Page 397 and 398:
Patient Education Background It has
- Page 399 and 400:
Web-Based Resources Background The